A5044398563- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Sexual Differentiation and Disorders
- Inflammatory mediators and NSAID effects
- Cancer, Stress, Anesthesia, and Immune Response
- Urinary Bladder and Prostate Research
- Attachment and Relationship Dynamics
- Eicosanoids and Hypertension Pharmacology
- Genital Health and Disease
- Aldose Reductase and Taurine
- Health Systems, Economic Evaluations, Quality of Life
- Urological Disorders and Treatments
- Ethics in Clinical Research
- Advanced Radiotherapy Techniques
- Sexual function and dysfunction studies
- Hormonal and reproductive studies
- Cancer survivorship and care
- Statistical Methods in Clinical Trials
- PARP inhibition in cancer therapy
- Xenotransplantation and immune response
- Global Cancer Incidence and Screening
- Immune Cell Function and Interaction
- Cancer and Skin Lesions
- Cardiac, Anesthesia and Surgical Outcomes
Western General Hospital
2008-2023
University of Edinburgh
2004-2023
NHS Lothian
2009-2020
Ninewells Hospital
2010
Edinburgh Royal Infirmary
2007
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radiotherapy with hormones outcomes.
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed 2664 men. Of these men, 1643 were enrolled trial to evaluate effectiveness treatments, with 545 randomly assigned receive active monitoring, 553 undergo prostatectomy, radiotherapy.
BackgroundLong-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer.MethodsPatient-reported of 1643 randomly assigned participants in the ProtecT (Prostate Testing Cancer and Treatment) trial were evaluated assess functional quality-of-life impacts prostatectomy, radiotherapy with neoadjuvant androgen deprivation, active monitoring. This article focuses on from 7 12 years using mixed effects linear logistic models.ResultsResponse rates...
The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. To determine report outcomes according treatment received in randomised choice cohorts. This study focuses on secondary care. Men clinically at one nine UK centres were invited participate the comparing AM, Two cohorts included 1643 who agreed be randomised; 997 declined randomisation chose...
To investigate the functional and quality of life (QoL) outcomes treatments for localised prostate cancer inform treatment decision-making.Men aged 50-69 years diagnosed with by prostate-specific antigen testing biopsies at nine UK centres in Prostate Testing Cancer Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) concurrent...
Background Prostate cancer is the most common among men in UK. Prostate-specific antigen testing followed by biopsy leads to overdetection, overtreatment as well undertreatment of disease. Evidence treatment effectiveness has lacked because paucity randomised controlled trials comparing conventional treatments. Objectives To evaluate treatments for localised prostate (active monitoring, radical prostatectomy and radiotherapy) aged 50–69 years. Design A prospective, multicentre...
Early detection and treatment of asymptomatic men with advanced high-risk prostate cancer (PCa) may improve survival rates. To determine outcomes for diagnosed PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial. Mortality was compared 492 followed up a median 7.4 yr to contemporaneous cohort UK Anglia Cancer Network (ACN) matched subset ACN. PCa-specific all-cause mortality using Kaplan-Meier analysis Cox's proportional hazards...
To report outcomes from a multiparametric (mp) magnetic resonance imaging (MRI)-based active surveillance programme that did not include performing protocol biopsies after the first confirmatory biopsy.
No AccessJournal of UrologyInvestigative Urology1 Jul 2004NITRIC OXIDE DONATING NONSTEROIDAL ANTI-INFLAMMATORY DRUGS INDUCE APOPTOSIS IN HUMAN PROSTATE CANCER CELL SYSTEMS AND PROSTATIC STROMA VIA CASPASE-3 JUSTINE SARAH ROYLE, JAMES A. ROSS, IAN ANSELL, PRASAD BOLLINA, DAVID N. TULLOCH, and FOUAD K. HABIB ROYLEJUSTINE ROYLE Financial interest and/or other relationship with Nicox. More articles by this author , ROSSJAMES ROSS ANSELLIAN ANSELL BOLLINAPRASAD BOLLINA TULLOCHDAVID TULLOCH...
We have developed a coculture system for primary fibroblast and epithelial cells derived from benign prostatic hyperplasia (BPH) that retained many of the characteristics intact human prostate. In contrast to separately cultured prostate cells, cocultures fibroblasts maintained messenger ribonucleic acid expression functional activity both isoenzymes 5 alpha-reductase (type I type II) as well androgen receptors prostate-specific antigen. Furthermore, levels antigen secreted by cocultured...
In human prostate, dehydroepiandrosterone (DHEA) is a substrate for two major metabolic pathways that produce functionally opposing sex steroids. one pathway, DHEA converted into potent androgens such as testosterone and 5α-dihydrotestosterone. the other, metabolized to 7α-hydroxy-DHEA (7HD). Recently, CYP7B, novel P450 enzyme originally characterized in mouse brain expressed rodent has been found be responsible all extrahepatic 7α-hydroxylase activity. this study, we have investigated...
The expression and localisation of mRNAs for 5 alpha reductase Type I (5 R-I) II R-II) isoenzymes in human benign prostatic hyperplasia (BPH) were investigated by RT-PCR mini hybridisation (ISH) using digoxigenin labelled riboprobes. In addition, we also examined the mRNA primary BPH cultures separated stroma/fibroblast epithelial cells to determine whether are appropriate models which investigate R activity regulation. results demonstrated conclusively presence encoding both all specimens...
There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer.
Objectives Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols determine leaves uncertainties for and clinicians. This study investigated men’s strategies coping the active monitoring (AM, a strategy within Prostate testing Treatment, ProtecT trial) over longer term implications optimising supportive care. Design Longitudinal serial in-depth qualitative interviews every 2–3...
Men who undergo surgery for prostate cancer frequently experience significant side-effects including urinary and sexual dysfunction. These difficulties can lead to anxiety, depression reduced quality of life. Many partners also psychological distress. An additional impact be on the couple relationship, with changes intimacy, unmet psychosexual supportive needs in relation recovery rehabilitation. The aim this exploratory randomised controlled trial pilot study is determine feasibility...
Abstract Background Optimal management strategies for clinically localised prostate cancer are debated. Using median 10-year data from the largest randomised controlled trial to date (ProtecT), lifetime cost-effectiveness of three major treatments (radical radiotherapy, radical prostatectomy and active monitoring) was explored according age risk subgroups. Methods A decision-analytic (Markov) model developed informed by clinical input. The economic evaluation adopted a UK NHS perspective...
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE To assess the outcomes and learning curve extraperitoneal endoscopic radical prostatectomy (EERP) using cumulative summation charts from a single tertiary referral centre. PATIENTS AND METHODS The data 300 consecutive men with localized prostate cancer who underwent EERP at Western General Hospital, Edinburgh, UK, between February 2006 July 2009 were prospectively maintained in database. collected included demographic details,...
ObjectivesRecruitment to pragmatic trials is often difficult, and little known about factors associated with key participation treatment decisions. These were explored in the Prostate cancer testing Treatment (ProtecT) study.Study Design SettingBaseline sociodemographic, patient-reported outcome, clinical history, prostate biopsy data collected for all patients eligible take part ProtecT trial, a comprehensive cohort design. Men who rejected randomization specified preferred option followed...
Paracrine interactions between primary cultured prostate epithelial cells and stromal fibroblasts were investigated in relation to morphology, growth, androgen sensitivity secretory activities using co-cultures which the two populations separated by a microporous membrane. In this new model system, both cell types maintained several aspects of differentiated phenotype including capacity express 5α-reductase iso-enzymes receptors, respond androgens secrete prostate-specific antigen cells....